title: Paracentesis before intravitreal injection of bevacizumab.
authors.forename: Yung-Ping
authors.initials: YP
authors.lastname: Tsui
authors.forename: Chun-Chi
authors.initials: CC
authors.lastname: Chiang
authors.forename: Yi-Yu
authors.initials: YY
authors.lastname: Tsai
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000867:Anterior Chamber / Q000601:surgery*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D008269:Macular Edema / Q000150:complications / Q000188:drug therapy; D009798:Ocular Hypertension / Q000517:prevention & control; D019152:Paracentesis / Q000379:methods*; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab